PL369402A1 - Nowe zastosowanie do leczenia choroby refluksowejprzełyku - Google Patents

Nowe zastosowanie do leczenia choroby refluksowejprzełyku

Info

Publication number
PL369402A1
PL369402A1 PL02369402A PL36940202A PL369402A1 PL 369402 A1 PL369402 A1 PL 369402A1 PL 02369402 A PL02369402 A PL 02369402A PL 36940202 A PL36940202 A PL 36940202A PL 369402 A1 PL369402 A1 PL 369402A1
Authority
PL
Poland
Prior art keywords
treatment
new application
reflux disease
gastroesophageal reflux
gastroesophageal
Prior art date
Application number
PL02369402A
Other languages
English (en)
Polish (pl)
Inventor
Anders Lehmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL369402A1 publication Critical patent/PL369402A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL02369402A 2001-11-23 2002-11-20 Nowe zastosowanie do leczenia choroby refluksowejprzełyku PL369402A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23

Publications (1)

Publication Number Publication Date
PL369402A1 true PL369402A1 (pl) 2005-04-18

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369402A PL369402A1 (pl) 2001-11-23 2002-11-20 Nowe zastosowanie do leczenia choroby refluksowejprzełyku

Country Status (20)

Country Link
US (1) US7358245B2 (enExample)
EP (1) EP1453497A1 (enExample)
JP (1) JP2005511632A (enExample)
KR (1) KR20050044582A (enExample)
CN (1) CN1610542A (enExample)
AR (1) AR037299A1 (enExample)
AU (1) AU2002353700A1 (enExample)
BR (1) BR0214319A (enExample)
CA (1) CA2466916A1 (enExample)
HU (1) HUP0402080A3 (enExample)
IL (1) IL161748A0 (enExample)
IS (1) IS7272A (enExample)
MX (1) MXPA04004774A (enExample)
NO (1) NO20042613L (enExample)
NZ (1) NZ532844A (enExample)
PL (1) PL369402A1 (enExample)
RU (1) RU2280443C2 (enExample)
TW (1) TW200407110A (enExample)
WO (1) WO2003043619A1 (enExample)
ZA (1) ZA200403785B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283056A1 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
KR20070118069A (ko) * 2004-12-09 2007-12-13 인시스 테라퓨틱스, 인코포레이티드 실온에서 안정한 드로나비놀 제형
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
JP4817495B2 (ja) * 1998-05-29 2011-11-16 ニューロサイエンシーズ・リサーチ・ファウンデーション・インコーポレーテッド 外因性カンナビノイドでの痛みの制御
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
TWI302913B (en) * 2000-06-15 2008-11-11 Schering Corp Thrombin receptor antagonists
AUPR118000A0 (en) 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
CA2466916A1 (en) 2003-05-30
US20040266861A1 (en) 2004-12-30
MXPA04004774A (es) 2004-07-30
EP1453497A1 (en) 2004-09-08
HUP0402080A2 (hu) 2005-02-28
IL161748A0 (en) 2005-11-20
US7358245B2 (en) 2008-04-15
AU2002353700A1 (en) 2003-06-10
KR20050044582A (ko) 2005-05-12
WO2003043619A1 (en) 2003-05-30
HUP0402080A3 (en) 2008-03-28
RU2004114843A (ru) 2005-05-27
WO2003043619A8 (en) 2005-03-17
TW200407110A (en) 2004-05-16
CN1610542A (zh) 2005-04-27
NZ532844A (en) 2005-12-23
BR0214319A (pt) 2004-11-03
JP2005511632A (ja) 2005-04-28
ZA200403785B (en) 2005-05-19
RU2280443C2 (ru) 2006-07-27
NO20042613L (no) 2004-08-13
IS7272A (is) 2004-05-19
AR037299A1 (es) 2004-11-03

Similar Documents

Publication Publication Date Title
NO20035156L (no) Fremgangsmåter for brønnbehandling
NO20035522D0 (no) Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom
NO20035609L (no) Fremgangsmate for kontinuerlig naftabehandling
NO20041368L (no) Azabicyklus-substituerte kondenserte heteroarylforbindelser for behandling av sykdom
KR100695846B9 (ko) 암 치료
NO20033203D0 (no) Terapeutiske heterocykliske forbindelser
NO20033204L (no) Terapeutiske kromonforbindelser
NO20033205L (no) Terapeutiske kromanforbindelser
DE60208982D1 (de) Fussbad
DE60223576D1 (de) Hautbehandlungszusammensetzung
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
PL369402A1 (pl) Nowe zastosowanie do leczenia choroby refluksowejprzełyku
DE10293222D2 (de) Zangenartiges chirurgisches Element
DE60114244D1 (de) Osteosynthesevorrichtung
DE50113918D1 (de) Quengel-Orthese
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
FR2837224B1 (fr) Bonde traitante
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
HK1067309A (en) Use for the treatment of gastroesophageal reflux disease
DE50206679D1 (de) Keramischer formkörper
SE0100006D0 (sv) Therapeutic compounds
SE0100007D0 (sv) Therapeutic compounds
SE0100009D0 (sv) Therapeutic compounds

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)